Skip to main content
. Author manuscript; available in PMC: 2006 Oct 22.
Published in final edited form as: Nat Immunol. 2005 Oct 2;6(11):1133–1141. doi: 10.1038/ni1261

Supplementary Figure 2. Blockage of IL-17 after disease onset reduces inflammation during EAE.

Supplementary Figure 2

(a) Anti-IL-17 treatment attenuates EAE incidence and severity. C57BL/6 mice were immunized with MOG/CFA and administered with pertussis toxin (see “Experimental Procedures”). Three doses of anti-IL-17 or rat IgG was administered after the disease onset (clinic score >1) on day 13, 14 and 16 post first immunization shown as arrows (n=5 in each group). (b) Less infiltration of CD4 T cells and macrophages were observed in anti-IL17 treatment group than rat IgG group. On day 17, mononuclear cells isolated from brains and spinal cords were analyzed for surface markers CD11b and CD4. Student t-test is shown as P values. (c) Splenocytes were ex vivo restimulated with MOG for 48 hours and cytokines expression were measured by ELISA. (d) Splenocyte proliferation in anti-IL-17 treatment group was similar with control group.